Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB | P24530 | 13/20 | 0.51 |
| ▸ | EDNRA | P25101 | 13/20 | 0.51 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 2/20 | 0.42 |
| ▸ | CTSB | P07858 | 2/20 | 0.42 |
| ▸ | CTSS | P25774 | 2/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6709092 | 0.82 | EDNRB (0.49) | EDNRBEDNRAALDH1A1 | |
| SCHEMBL6708689 | 0.82 | EDNRB (0.47) | EDNRBEDNRA | |
| SCHEMBL6708978 | 0.79 | EDNRB (0.46) | EDNRBEDNRA | |
| SCHEMBL6710406 | 0.78 | EDNRB (0.56) | EDNRBEDNRA | |
| SCHEMBL6712225 | 0.78 | EDNRB (0.62) | EDNRBEDNRA | |
| SCHEMBL6712119 | 0.77 | EDNRB (0.45) | EDNRBEDNRA | |
| SCHEMBL6712034 | 0.77 | EDNRB (0.61) | EDNRBEDNRA | |
| SCHEMBL8200442 | 0.73 | EDNRB (0.64) | EDNRBEDNRA | |
| SCHEMBL6707532 | 0.71 | EDNRB (0.51) | EDNRBEDNRA | |
| SCHEMBL8100747 | 0.70 | EDNRB (0.67) | EDNRBEDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040034076-A1 | Novel carbamates and carbamides, production and use thereof as endothelin receptor antagonists | ABBOTT GMBH & CO. KG (DE) | 2004-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034076-A1 | Novel carbamates and carbamides, production and use thereof as endothelin receptor antagonists | EDNRA, EDNRB, ECE1 | EDNRB 2/4885EDNRA 1/4885TACR1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.